Given the urgent need for disease-modifying therapies for TDP-43 proteinopathies, our findings offer an expanded and mechanistically rich framework for therapeutic intervention—revealing previously hidden vulnerabilities in the TDP-43 aggregation pathway that are now actionable through specific proteostasis-based strategies. The gene discussed is TARDBP; the disease is proteostasis deficiencies.